Germany's Activaero and Forest Laboratories to co-market new Colistin nebuliser for cystic fibrosis
This article was originally published in Scrip
Germany's Activaero has signed an agreement with Forest Healthcare to co-market Activaero's Akita Jet inhaler with colistin for high-dose therapy of cystic fibrosis in Germany. The partners said they have been able to demonstrate the advantages of Colistin CF (the new product's trade name) over similar inhalers and plan to introduce it to centres for the treatment of cystic fibrosis.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.